Initially studied in age‐related diseases, neurodegeneration [42, 43], inflammatory disorders [44], myopathies [45], and diverse cancers [46, 47, 48], SIRT1 is established as a key regulatory factor and therapeutic target in GBM multiforme pathogenesis. This evidence concerns the gene SIRT1 and myopathy.